<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231787</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PLA-2016-86</org_study_id>
    <nct_id>NCT03231787</nct_id>
  </id_info>
  <brief_title>Clinical Trial in Antiaggregated Patients With Proximal Femur Fracture Evaluating a Strategy to Shorten Time Until Surgery</brief_title>
  <acronym>AFFEcT</acronym>
  <official_title>Randomized Parallel Multicenter Trial in Antiaggregated Patients With Proximal Femur Fracture Evaluating a Strategy to Shorten Time Until Surgery (AFFEcT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Clinical Research Network - SCReN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      National, randomized, open, parallel, multicenter clinical trial of two comparison groups&#xD;
      that will evaluate the feasibility of a strategy based on a diagnostic test to shorten the&#xD;
      surgery time in antiaggregated patients with proximal femur fracture.&#xD;
&#xD;
      The experimental group will undergo surgery as soon as platelet aggregability, according to&#xD;
      the PLATELETWORKS® method is correct within 24-48 hours.&#xD;
&#xD;
      The control group will undergo surgery according to the usual practice of the center taking&#xD;
      into account the safety time of the antiplatelet agent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Anticipated">June 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from emergency admission to surgery</measure>
    <time_frame>Up to 120 hours</time_frame>
    <description>Time from emergency admission to surgery will be measured in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>Through hospitalization, an average of 5 days</time_frame>
    <description>Total blood loss calculated by Nadler's formula from date of surgery until date of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion</measure>
    <time_frame>Through hospitalization, an average of 5 days</time_frame>
    <description>Need for blood transfusion during hospitalization and transfused units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative hemoglobin</measure>
    <time_frame>12 hours before surgery</time_frame>
    <description>Measurement of preoperative hemoglobin during 12 h before surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hemoglobin</measure>
    <time_frame>From 12 hours after surgery until date of discharge, an average of 5 days</time_frame>
    <description>Measurement of postoperative hemoglobin until discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical wound complications</measure>
    <time_frame>1 week and 30 days after surgery</time_frame>
    <description>It includes:&#xD;
Wound infection&#xD;
Wound dehiscence&#xD;
Reoperation due to wound complications&#xD;
Postoperative pain&#xD;
Safety: including the incidence of deep venous thrombosis during admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical complications</measure>
    <time_frame>1 week and 30 days after surgery</time_frame>
    <description>Myocardial infarction, stroke, pulmonary embolism, pneumonia / respiratory infections, urinary tract infections, sepsis, new onset pressure ulcers, acute renal failure, heart failure, delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Functionality</measure>
    <time_frame>From date of admission until the day before surgery, an average of 2 days</time_frame>
    <description>Measurement of platelet functionality with plateletworks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Preoperative, 5 days after surgery, and 1, 6 and 12 months after surgery</time_frame>
    <description>Quality of life measured by EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to admission to patient movilization</measure>
    <time_frame>From date of admission until the date of first movilization, an average of 3 days</time_frame>
    <description>Time to admission to patient movilization measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>All causes mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness ratio</measure>
    <time_frame>1 year</time_frame>
    <description>Cost effectiveness ratio (Δ cost / Δ effectiveness)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Femur Fracture</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.&#xD;
If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.&#xD;
If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will wait for the safety time of the drug according to the usual practice of the center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Platelet function assay</intervention_name>
    <description>Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.&#xD;
It will be used to measure platelet function after withdrawal of the antiplatelet agent.&#xD;
If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Plateletworks®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Patients of both sexes&#xD;
&#xD;
          -  Patients with a proximal femoral fracture requiring surgery&#xD;
&#xD;
          -  Patients receiving antiplatelet agents at the time of admission to the emergency room:&#xD;
             AAS&gt; 100 mg / d (Aspirin®), Trifusal&gt; 300 mg / d (Digren®; Edigen®), clopidogrel&#xD;
             (Plavix®), prasugrel ®), ticagrelor (Brilique ®) and ticlopidine (Tiklid ®).&#xD;
&#xD;
          -  Patients who give their signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple fractures&#xD;
&#xD;
          -  Pathological fractures&#xD;
&#xD;
          -  Patients receiving vitamin K antagonist oral anticoagulants (warfarin and&#xD;
             acenocoumarol) or new oral anticoagulants (apixaban, rivaroxaban and dabigatran) or&#xD;
             who have acquired congenital or acquired coagulopathy&#xD;
&#xD;
          -  Patients with AAS ≤100mg, trifusal ≤300mg&#xD;
&#xD;
          -  Patients who do not give their informed consent or their legal guardian&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria J Martinez Zapata, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Althaia, Xarxa Assistencial Universitària de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

